甘李药业实控人方一周间完成减持1%股份 套现2.9亿元

Core Points - Gannee Pharmaceutical (甘李药业) announced the completion of a share reduction plan by its shareholder, Beijing Xutong Hongda Technology Co., Ltd. (旭特宏达), which reduced its holdings by 6,010,622 shares, representing 1% of the company's total share capital [1][2] - The share reduction occurred between April 22, 2025, and April 30, 2025, with a price range of 44.85 to 49.81 yuan per share, totaling approximately 290.35 million yuan [1][2] - After the reduction, Xutong Hongda holds 35,473,235 shares, accounting for 5.90% of the total share capital [2] Shareholder Information - Before the reduction, Xutong Hongda and its concerted party, Gan Zhongru, held a combined total of 247,127,614 shares, which is 41.11% of the total share capital [3] - Xutong Hongda owned 41,483,857 shares (6.90%), while Gan Zhongru held 205,643,757 shares (34.21%) [3] - Gan Zhongru is the largest shareholder of Gannee Pharmaceutical, and Xutong Hongda is the second largest [3] Fundraising Activities - Gannee Pharmaceutical went public on June 29, 2020, raising a total of 2.545 billion yuan, with a net amount of 2.441 billion yuan after expenses [4] - The funds raised were allocated for various projects, including marketing network construction and product registration in the U.S. [4] - In 2023, the company issued 28,508,550 shares at a price of 27.12 yuan per share, raising approximately 773.15 million yuan, with a net amount of about 759.73 million yuan after expenses [5]